Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023

Winthrop, K.L.; Mease, P.; Kerschbaumer, A.; Voll, R.E.; Breedveld, F.C.; Smolen, J.S.; ... ; Gravallese, E.M. (2023)

Article / Letter to editor

The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology, immunology, infectious diseases, epidemiology, molecular biology and other specialties relating to all aspects of immune-mediated inflammatory diseases. We held breakout sessions in five rheumatological disease-specific groups including: rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpa), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and vasculitis, and osteoarthritis (OA). In each group, experts were asked to identify and prioritise current unmet needs in clinical and translational research. An overarching theme across all disease states is the continued need for clinical trial design innovation with regard to therapeutics, endpoint and disease endotypes. Within RA, unmet needs comprise molecular classification of disease pathogenesis and activity, pre-/early RA strategies, more refined pain profiling and innovative trials designs to deliver on precision medicine. Continued scientific questions within PsA include evaluating the genetic, immunophenotypic, clinical signatures that predict development of PsA in patients with psoriasis, and the evaluation of combination therapies for difficult-to-treat disease. For axSpA, there continues to be the need to understand the role of interleukin-23 (IL-23) in pathogenesis and the genetic relationship of the IL-23-receptor polymorphism with other related systemic inflammatory diseases (eg, inflammatory bowel disease). A major unmet need in the OA field remains the need to develop the ability to reliably phenotype and stratify patients for inclusion in clinical trials. SLE experts identified a number of unmet needs within clinical trial design including the need for allowing endpoints that reflect pharmacodynamic/functional outcomes (eg, inhibition of type I interferon pathway activation; changes in urine biomarkers). Lastly, within SSc and vasculitis, there is a lack of biomarkers that predict response or disease progression, and that allow patients to be stratified for therapies. There remains a strong need to innovate clinical trial design, to identify systemic and tissue-level biomarkers that predict progression or response to therapy, endotype disease, and to continue developing therapies and therapeutic strategies for those with treatment-refractory disease. This document, based on expert consensus, should provide a roadmap for prioritising scientific endeavour in the field of rheumatology.

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Spondyloarthritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

• All authors: Winthrop, K.L.; Mease, P.; Kerschbaumer, A.; Voll, R.E.; Breedveld, F.C.; Smolen, J.S.; Gottenberg, J.E.; Baraliakos, X.; Kiener, H.P.; Aletaha, D.; Isaacs, J.D.; Buch, M.H.; Crow, M.K.; Kay, J.; Crofford, L.; Vollenhoven, R.F. van; Ospelt, C.; Siebert, S.; Kloppenburg, M.; Mcinnes, I.B.; Huizinga, T.W.J.; Gravallese, E.M.
• Date: 2023-12-20
• Journal: Annals of the Rheumatic Diseases
• DOI: doi:10.1136/ard-2023-224916
• Link: https://ard.bmj.com/content/early/2023/12/20/ard-2023-224916